Livingston, Nicholas R. http://orcid.org/0000-0002-6582-2545
Kiemes, Amanda http://orcid.org/0000-0001-6819-8090
Devenyi, Gabriel A. http://orcid.org/0000-0002-7766-1187
Knight, Samuel
Lukow, Paulina B.
Jelen, Luke A.
Reilly, Thomas
Dima, Aikaterini
Nettis, Maria Antonietta http://orcid.org/0000-0002-5401-8391
Casetta, Cecilia
Agyekum, Tyler
Zelaya, Fernando
Spencer, Thomas
De Micheli, Andrea
Fusar-Poli, Paolo
Grace, Anthony A. http://orcid.org/0000-0003-1864-5504
Williams, Steve C. R. http://orcid.org/0000-0003-4299-1941
McGuire, Philip http://orcid.org/0000-0003-4381-0532
Egerton, Alice http://orcid.org/0000-0003-2939-064X
Chakravarty, M. Mallar
Modinos, Gemma http://orcid.org/0000-0002-7870-066X
Funding for this research was provided by:
RCUK | Medical Research Council
Wellcome Trust
Royal Society
Article History
Received: 11 January 2024
Revised: 11 March 2024
Accepted: 8 April 2024
First Online: 24 April 2024
Competing interests
: GM has received consulting fees from Boehringer Ingelheim. AE has received consulting fees from Leal Therapeutics. AAG has received funds from Lundbeck, Pfizer, Lilly, Roche, Janssen, Alkermes, Newron, Takeda and Merck. SCRW has recently received research funding from Boehringer Ingelheim and GE Healthcare to perform investigator-led research. All other authors have nothing to disclose.